A Soft Anthropomorphic & Tactile Fingertip for Low-Cost Prosthetic & Robotic Applications

Nowadays, prosthetic and robotic hands have reached an amazing dexterity and grasping capability. However, to enhance a proper tactile 'experience', dexterity should be supported by proper sensation of daily life objects which such devices are supposed to manipulate. Here we propose a low cost anthropomorphic solution for the integration of a force sensor within a biologically inspired fingertip. A commercial force resistive sensor is embedded within a human-like soft fingertip made of silicone: the housing of the sensor - a 3D printed bay embedded within the fingertip - is analyzed via Finite Element Analysis and optimized to enhance sensor response. Experiments validate the design and proposed solution

A Sustainable & Biologically Inspired Prosthetic Hand for Healthcare

There are many persons in the world affected by amputation. Upper limb amputations require high cost prosthetic devices in order to provide significant motor recovery. We propose a sustainable design and control of a new anthropomorphic prosthetic hand: all components are modular and exchangeable and they can be assembled by non-expert users. Phalanges & articulations of the fingers and the palm are manufactured via a 3D printing process in Acrylonitrile Butadiene Styrene (ABS) or Polyactic Acid (PLA) materials. The design is optimized in order to provide human-like motion and grasping taxonomy through linear actuators and flexion tendon mechanisms, which are embedded within the palm. HardWare (HW) and Software (SW) open sourced units for ElectroMyography (EMG) input and control can be combined with a user-friendly and intuitive Graphical User Interface (GUI) to enable amputees handling the prosthesis. To reduce the environmental impact of the device lifetime cycle, the material and energy consumption were optimized by adopting: simple design & manufacturing, high dexterity, open source HW and SW, low cost components, anthropomorphic design

Development of a sustainable and ergonomic interface for the EMG control of prosthetic hands

Most of the interfaces of the current upper limb prosthetic device are rigid. However, human limbs and body are a combination of rigid and soft parts. Such a combination inherently suggests to implement soft ergonomic interfaces between the human body and such prosthetic devices. To this aim we have developed a novel set of wearable solutions, including a textile sleeve embedding EMG electrodes for the control of hand prosthesis. This interface has been integrated and preliminary tested in order to control a 5 d.o.f. low cost robotic hand

Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19 : an open-label randomized controlled trial

Background The efficacy and safety of complement inhibition in COVID-19 patients is unclear. Methods A multicenter randomized controlled, open-label trial. Hospitalized COVID-19 patients with signs of systemic inflammation and hypoxemia (PaO2/FiO(2) below 350 mmHg) were randomized (2:1 ratio) to receive standard of care with or without the C5 inhibitor zilucoplan daily for 14 days, under antibiotic prophylaxis. The primary outcome was improvement in oxygenation at day 6 and 15. Results 81 patients were randomly assigned to zilucoplan (n = 55) or the control group (n = 26). 78 patients were included in the safety and primary analysis. Most were men (87%) and the median age was 63 years. The mean improvement in PaO2/FiO(2) from baseline to day 6 was 56.4 mmHg in the zilucoplan group and 20.6 mmHg in the control group (mean difference + 35.8; 95% confidence interval (CI) - 9.4 to 80.9; p = 0.12), an effect also observed at day 15. Day 28 mortality was 9% in the zilucoplan and 21% in the control group (odds ratio 0.4; 95% CI 0.1 to 1.5). At long-term follow up, the distance walked in a 6-min test was 539.7 m in zilucoplan and 490.6 m in the control group (p = 0.18). Zilucoplan lowered serum C5b-9 (p < 0.001) and interleukin-8 (p = 0.03) concentration compared with control. No relevant safety differences between the zilucoplan and control group were identified. Conclusion Administration of zilucoplan to COVID-19 patients in this proof-of-concept randomized trial was well tolerated under antibiotic prophylaxis. While not reaching statistical significance, indicators of respiratory function (PaO2/FiO(2)) and clinical outcome (mortality and 6-min walk test) suggest that C5 inhibition might be beneficial, although this requires further research in larger randomized studies